Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.

The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.

The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.